{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:25:38Z","timestamp":1787502338544,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1990,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"FNCLCC, French Federation of Cancer Centers","award":["no. 2010"],"award-info":[{"award-number":["no. 2010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1093\/annonc\/mdu108","type":"journal-article","created":{"date-parts":[[2014,3,8]],"date-time":"2014-03-08T20:13:12Z","timestamp":1394309592000},"page":"1222-1228","source":"Crossref","is-referenced-by-count":20,"title":["Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database"],"prefix":"10.1016","volume":"25","author":[{"given":"P.A.","family":"Cassier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Polivka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marsoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morales-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gallerani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu108_bb0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cncr.25538","article-title":"Trends in survival for patients with metastatic soft-tissue sarcoma","volume":"117","author":"Italiano","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu108_bb0015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu108_bb0020","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu108_bb0025","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1200\/jco.2008.26.15_suppl.10592","article-title":"Response to sunitinib malate (SM) in alveolar soft part sarcoma (ASPS)","volume":"26","author":"Stacchiotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu108_bb0030","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu108_bb0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.2010.34.5074","article-title":"Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors","volume":"30","author":"Olmos","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu108_bb0040","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu108_bb0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","article-title":"Risks and benefits of phase 1 oncology trials, 1991 through 2002","volume":"352","author":"Horstmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu108_bb0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"Van Glabbeke","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu108_bb0055","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.1995.13.5.1062","article-title":"Perceptions of cancer patients and their physicians involved in phase I trials","volume":"13","author":"Daugherty","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu108_bb0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bjc.6602423","article-title":"Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy","volume":"92","author":"Nurgat","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu108_bb0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.hoc.2005.03.001","article-title":"Imaging and response in soft tissue sarcomas","volume":"19","author":"Schuetze","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdu108_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.13-S2-1","article-title":"SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective","volume":"13","author":"Benjamin","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdu108_bb0075","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1002\/cncr.27624","article-title":"Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy","volume":"118","author":"Stacchiotti","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu108_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu108_bb0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00280-010-1484-9","article-title":"Clinical benefit of early phase clinical trial participation for advanced sarcoma patients","volume":"68","author":"Jones","year":"2011","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:43:45Z","timestamp":1624506225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0923753419365688"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu108","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718304595.793526413","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}